Anaxomics is a company specialized in bioinformatics and systems biology providing services for drug discovery, pre-clinical and clinical development. Anaxomics offers a unique combination of cutting-edge artificial intelligence developments and the work of a highly skilled team of professionals to provide a wide array of continuously refined services. Anaxomics offers its broad expertise in systems biology and its state-of-the-art biocomputational methodologies to provide a new insight in the understanding of the complexity of biological processes and innovative solutions to take our understanding of drugs and diseases to a new level. In DISCOVERIE, large-scale data will be gathered from across a range of disciplines, stored, combined, and used in new and creative large-scale informatics applications. The analytics being performed on such data promise to improve the precision and specificity of health monitoring, telemedicine, and medical decision-making. The analytic developments that Anaxomics provides align with these objectives, specifically the In-silico approaches provided by Anaxomics will contribute to decipher molecular mechanistic links between comorbid conditions and the identification of biomarkers. Systems biology based analysis presents a natural complement to ongoing efforts in cell biology and establishes a framework for mechanistic understanding of the genome-to-phenome relationship. Anaxomics has the infrastructure and equipment necessary to cover all tasks assigned in this project, including: secured IT facilities to manage confidential information, cluster-computing equipment, data-storage facilities, bioinformatics software (proprietary) and databases (proprietary). Anaxomics works under standard operation procedures and is Applus (ISO 9001) certified.
